Alnylam stock sinks nearly 7% after Amvuttra revenue miss; what to watch next for ALNY
Alnylam Pharmaceuticals’ shares fell sharply on Monday after the drugmaker’s preliminary fourth-quarter sales for its flagship heart drug Amvuttra came in below Wall Street expectations.